Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical and financing updates. That stability reflects a cautious analyst stance that reins in more aggressive valuation assumptions while still recognizing the early stage profile of Ocugen’s pipeline. As you read on, you will see how this updated narrative, and the data behind it, can help you track Ocugen’s evolving story. Analyst Price Targets don't always capture the full...
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
226last 24h
1319last 7d
227● bullish (7d)
148● bearish (7d)
205publishers
Simply Wall St.57d agoneutral
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst ViewZacks104d agobullish
Ocugen (OCGN) Upgraded to Buy: Here's WhyOcugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).